Skip to content
Triangle logo TriangleGet started
← Full study record

NCT07217119 · OUTCOME

DE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Picogram / millilitre (pg/mL)
Interval / dispersion
Standard Deviation
Time frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks)

What was measured

Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).

Analysis population: PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.

Groups in this outcome

1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).

2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6

Reported measurements

C1 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.000.000Not reportedNot reportedNot reported
C1 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab348.33174.415Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab362.90152.074Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab411.83239.787Not reportedNot reportedNot reported
C1 D1, 2 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab397.67219.583Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab439.60151.680Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab575.33386.115Not reportedNot reportedNot reported
C1 D1, 24 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1126.111529.405Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1059.60861.657Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab917.67439.953Not reportedNot reportedNot reported
C1 D4, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab313.38102.131Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab645.00434.713Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab628.50147.267Not reportedNot reportedNot reported
C1 D8, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab116.4938.063Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab196.9257.691Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab247.5066.768Not reportedNot reportedNot reported
C2 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.000.000Not reportedNot reportedNot reported
C2 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab295.1484.044Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab386.75212.491Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab368.67360.003Not reportedNot reportedNot reported
C4 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.000.000Not reportedNot reportedNot reported
C4 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab513.67321.674Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab362.00136.936Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab367.67145.308Not reportedNot reportedNot reported
C6 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.000.000Not reportedNot reportedNot reported
C6 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab435.00106.066Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab318.3340.857Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab504.67604.086Not reportedNot reportedNot reported
C9 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.000.000Not reportedNot reportedNot reported
C9 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab207.5021.920Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab455.00310.066Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab392.00229.103Not reportedNot reportedNot reported
C12 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab1
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.00NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C12 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab1
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab298.0015.556Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab194.507.778Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.00NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C18 C1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
EoT (up to ~ 281 weeks)

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Picogram / millilitre (pg/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab77.60116.055Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.000.000Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab110.33191.103Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.000
        value
        0.00
      2. group Id
        OG001
        spread
        0.000
        value
        0.00
      3. group Id
        OG002
        spread
        0.000
        value
        0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, PRE-DOSE
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        174.415
        value
        348.33
      2. group Id
        OG001
        spread
        152.074
        value
        362.90
      3. group Id
        OG002
        spread
        239.787
        value
        411.83
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, END OF INFUSION
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        219.583
        value
        397.67
      2. group Id
        OG001
        spread
        151.680
        value
        439.60
      3. group Id
        OG002
        spread
        386.115
        value
        575.33
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, 2 HOURS
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        1529.405
        value
        1126.11
      2. group Id
        OG001
        spread
        861.657
        value
        1059.60
      3. group Id
        OG002
        spread
        439.953
        value
        917.67
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, 24 HOURS
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        102.131
        value
        313.38
      2. group Id
        OG001
        spread
        434.713
        value
        645.00
      3. group Id
        OG002
        spread
        147.267
        value
        628.50
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D4, ANYTIME SAMPLE
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        38.063
        value
        116.49
      2. group Id
        OG001
        spread
        57.691
        value
        196.92
      3. group Id
        OG002
        spread
        66.768
        value
        247.50
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D8, ANYTIME SAMPLE
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.000
        value
        0.00
      2. group Id
        OG001
        spread
        0.000
        value
        0.00
      3. group Id
        OG002
        spread
        0.000
        value
        0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        9
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C2 D1, PRE-DOSE
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        84.044
        value
        295.14
      2. group Id
        OG001
        spread
        212.491
        value
        386.75
      3. group Id
        OG002
        spread
        360.003
        value
        368.67
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C2 D1, END OF INFUSION
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.000
        value
        0.00
      2. group Id
        OG001
        spread
        0.000
        value
        0.00
      3. group Id
        OG002
        spread
        0.000
        value
        0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, PRE-DOSE
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        321.674
        value
        513.67
      2. group Id
        OG001
        spread
        136.936
        value
        362.00
      3. group Id
        OG002
        spread
        145.308
        value
        367.67
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, END OF INFUSION
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.000
        value
        0.00
      2. group Id
        OG001
        spread
        0.000
        value
        0.00
      3. group Id
        OG002
        spread
        0.000
        value
        0.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C6 D1, PRE-DOSE
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        106.066
        value
        435.00
      2. group Id
        OG001
        spread
        40.857
        value
        318.33
      3. group Id
        OG002
        spread
        604.086
        value
        504.67
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C6 D1, END OF INFUSION
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      10
    3. group Id
      OG002
      value
      6
    units
    Participants
description
Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).
dispersion Type
Standard Deviation
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
    id
    OG000
    title
    1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  2. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG001
    title
    2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  3. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG002
    title
    2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type
MEAN
population Description
PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.
reporting Status
POSTED
time Frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks)
title
DE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
type
SECONDARY
unit Of Measure
Picogram / millilitre (pg/mL)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice